Arsenic trioxide (As2O3) as a maintenance therapy for adult T cell leukemia/lymphoma
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1742-4690
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Arsenic trioxide (As2O3) as a maintenance therapy for adult T cell leukemia/lymphoma ; volume:17 ; number:1 ; day:21 ; month:3 ; year:2020 ; pages:1-5 ; date:12.2020
Retrovirology ; 17, Heft 1 (21.3.2020), 1-5, 12.2020
- Urheber
-
Marçais, Ambroise
Cook, Lucy
Witkover, Aviva
Asnafi, Vahid
Avettand-Fenoel, Véronique
Delarue, Richard
Cheminant, Morgane
Sibon, David
Frenzel, Laurent
Thé, Hugues de
Bangham, Charles R. M.
Bazarbachi, Ali
Hermine, Olivier
Suarez, Felipe
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12977-020-0513-y
- URN
-
urn:nbn:de:101:1-2020061321035393791248
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:47 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Marçais, Ambroise
- Cook, Lucy
- Witkover, Aviva
- Asnafi, Vahid
- Avettand-Fenoel, Véronique
- Delarue, Richard
- Cheminant, Morgane
- Sibon, David
- Frenzel, Laurent
- Thé, Hugues de
- Bangham, Charles R. M.
- Bazarbachi, Ali
- Hermine, Olivier
- Suarez, Felipe
- SpringerLink (Online service)
Ähnliche Objekte (12)
Importance of monitoring arsenic methylation metabolism in acute promyelocytic leukemia patients receiving the treatment of arsenic trioxide
Azacytidine sensitizes acute myeloid leukemia cells to arsenic trioxide by up-regulating the arsenic transporter aquaglyceroporin 9
Arsenic trioxide promoting ETosis in acute promyelocytic leukemia through mTOR-regulated autophagy
ATO (Arsenic Trioxide) effects on promyelocytic leukemia nuclear bodies reveals antiviral intervention capacity
ATO (Arsenic Trioxide) Effects on Promyelocytic Leukemia Nuclear Bodies Reveals Antiviral Intervention Capacity
Arsenic trioxide inhibits EBV reactivation and promotes cell death in EBV-positive lymphoma cells
Basic Mechanisms of Arsenic Trioxide (ATO)-Induced Apoptosis in Human Leukemia (HL-60) Cells
PML-RARA mutations confer varying arsenic trioxide resistance
Clinical Indicators of Hepatotoxicity in Newly Diagnosed Acute Promyelocytic Leukemia Patients Undergoing Arsenic Trioxide Treatment
Vitamin D3 potentiates the antitumorigenic effects of arsenic trioxide in human leukemia (HL-60) cells
Relapsed acute promyelocytic leukemia in a hemodialysis-dependent patient treated with arsenic trioxide: a case report
Oxidative stress induced by the chemotherapeutic agent arsenic trioxide
Importance of monitoring arsenic methylation metabolism in acute promyelocytic leukemia patients receiving the treatment of arsenic trioxide
Azacytidine sensitizes acute myeloid leukemia cells to arsenic trioxide by up-regulating the arsenic transporter aquaglyceroporin 9
Arsenic trioxide promoting ETosis in acute promyelocytic leukemia through mTOR-regulated autophagy
ATO (Arsenic Trioxide) effects on promyelocytic leukemia nuclear bodies reveals antiviral intervention capacity
ATO (Arsenic Trioxide) Effects on Promyelocytic Leukemia Nuclear Bodies Reveals Antiviral Intervention Capacity
Arsenic trioxide inhibits EBV reactivation and promotes cell death in EBV-positive lymphoma cells
Basic Mechanisms of Arsenic Trioxide (ATO)-Induced Apoptosis in Human Leukemia (HL-60) Cells
PML-RARA mutations confer varying arsenic trioxide resistance
Clinical Indicators of Hepatotoxicity in Newly Diagnosed Acute Promyelocytic Leukemia Patients Undergoing Arsenic Trioxide Treatment
Vitamin D3 potentiates the antitumorigenic effects of arsenic trioxide in human leukemia (HL-60) cells
Relapsed acute promyelocytic leukemia in a hemodialysis-dependent patient treated with arsenic trioxide: a case report
Oxidative stress induced by the chemotherapeutic agent arsenic trioxide
Importance of monitoring arsenic methylation metabolism in acute promyelocytic leukemia patients receiving the treatment of arsenic trioxide
Azacytidine sensitizes acute myeloid leukemia cells to arsenic trioxide by up-regulating the arsenic transporter aquaglyceroporin 9
Arsenic trioxide promoting ETosis in acute promyelocytic leukemia through mTOR-regulated autophagy
ATO (Arsenic Trioxide) effects on promyelocytic leukemia nuclear bodies reveals antiviral intervention capacity
ATO (Arsenic Trioxide) Effects on Promyelocytic Leukemia Nuclear Bodies Reveals Antiviral Intervention Capacity
Arsenic trioxide inhibits EBV reactivation and promotes cell death in EBV-positive lymphoma cells
Basic Mechanisms of Arsenic Trioxide (ATO)-Induced Apoptosis in Human Leukemia (HL-60) Cells
PML-RARA mutations confer varying arsenic trioxide resistance
Clinical Indicators of Hepatotoxicity in Newly Diagnosed Acute Promyelocytic Leukemia Patients Undergoing Arsenic Trioxide Treatment
Vitamin D3 potentiates the antitumorigenic effects of arsenic trioxide in human leukemia (HL-60) cells
Relapsed acute promyelocytic leukemia in a hemodialysis-dependent patient treated with arsenic trioxide: a case report